Company Profile
Syndax Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- SNDX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
19.76 USD (-0.80%)
Close
Last updated: August 6, 2026
1.63B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SNDX closed down 0.80% at $19.76. No new same-company headline was identified in the current news window.
Company overview
Commercial Oncology Portfolio
Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo.
Revuforj
Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers. Ongoing studies evaluate frontline combinations, post-transplant maintenance and additional molecular subgroups, including NPM1-mutant, KMT2A-rearranged and NUP98-rearranged disease.
Niktimvo
Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease. Syndax is testing the molecule in newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis to expand beyond its initial indication.
Frontline Registrational Strategy
Syndax is advancing pivotal trials intended to establish revumenib in frontline acute myeloid leukemia. It also plans the RAVEN study as part of the asset’s broader development program.
Future catalysts
New revumenib real-world, frontline and post-transplant maintenance data expected in the second quarter of 2026.
Additional revumenib data presentations from ongoing studies during the second half of 2026.
Initiation of the RAVEN trial expected in the second half of 2026.
Topline Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and newly diagnosed chronic GVHD expected in the fourth quarter of 2026.
Recent news
- 01
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Syndax Pharmaceuticals
- 02
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Source: Syndax Pharmaceuticals
- 03
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Source: Syndax Pharmaceuticals
- 04
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Source: Syndax Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
Syndax Pharmaceuticals (SNDX) most recently closed at 19.76 USD, a -0.80% move versus the previous session.
What is the market cap of Syndax Pharmaceuticals (SNDX)?
Syndax Pharmaceuticals currently has a market capitalization of 1.63B USD on BioPharmSignal.
What does Syndax Pharmaceuticals do?
Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers....
On which exchange is SNDX stock listed?
Syndax Pharmaceuticals (SNDX) is associated with NASDAQ, United States, Biopharma.
What is CSF-1?
Niktimvo Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease.
Which conditions is Syndax Pharmaceuticals targeting with CSF-1?
Syndax Pharmaceuticals is associated with oncology, genetic disease based on its company overview and current catalyst commentary.
How does Syndax Pharmaceuticals describe recent progress with CSF-1?
New revumenib real-world, frontline and post-transplant maintenance data expected in the second quarter of 2026. Additional revumenib data presentations from ongoing studies during the second half of 2026. Initiation of the RAVEN trial expected in the second half of 2026. Topline Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and newly...
What is revumenib?
Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers.